您的购物车当前为空
Recainam 是一种可口服的新型且具有有效的 I 类抗心律失常活性的化合物。
别名 瑞卡南
Recainam 是一种可口服的新型且具有有效的 I 类抗心律失常活性的化合物。

| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 530 | 现货 | |
| 5 mg | ¥ 1,230 | 现货 | |
| 10 mg | ¥ 1,830 | 现货 | |
| 25 mg | ¥ 3,530 | 现货 | |
| 50 mg | ¥ 4,800 | 现货 | |
| 100 mg | ¥ 6,830 | 现货 | |
| 500 mg | ¥ 13,700 | 现货 |
TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
该分子属于定制产品。TargetMol拥有优秀的合成团队,经验和能力,可以为您提供高性价比的产品。
如您有任何问题,欢迎咨询,我们将竭诚为您服务。| 产品描述 | Recainam is a novel, orally available compound with potent class I antiarrhythmic activity. |
| 体内活性 | Recainam was administered at a loading dose of 4.5 mg/kg/hour over 40 minutes, followed by a maintenance infusion of 0.9 mg/kg/hour for 23 hours and 20 minutes. The mean frequency of total VPCs decreased by 92.6% and the mean frequency of runs decreased by 99.9% during the maintenance infusion. Suppressions of > or = 70% of total VPCs and > or = 90% of runs were maintained over the 23-hour, 20-minute maintenance infusion period in 16 of the 18 patients. During the maintenance infusion, hourly group plasma Recainam concentrations ranged from mean +/- SD 2.6 +/- 0.7 to 3.4 +/- 0.9 micrograms/ml. The following pharmacokinetic parameters were obtained: terminal elimination half-life, 5.0 +/- 0.8 hours; systemic clearance, 0.27 +/- 0.08 liter/hour/kg; and central and steady-state volume of distribution, 0.32 +/- 0.11 and 1.4 +/- 0.4 liter/kg, respectively.[2] |
| 别名 | 瑞卡南 |
| 分子量 | 263.38 |
| 分子式 | C15H25N3O |
| CAS No. | 74738-24-2 |
| Smiles | N(C(NCCCNC(C)C)=O)C1=C(C)C=CC=C1C |
| 存储 | ||||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 45 mg/mL (170.86 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。 | ||||||||||||||||||||||||||||||||||||
对于不同动物的给药剂量换算,您也可以参考 更多